"We exist to help develop new therapies and breakthrough drugs so that people around the world can live better, healthier lives."

During the past decade, Charter Research conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 5 clinical trials were completed, i.e. on average, 17.9% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 5 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Charter Research" #1 sponsor was "Eli Lilly and Company" with 6 trials, followed by "Alector Inc." with 2 trials sponsored, "BioVie Inc." with 2 trials sponsored, "Cognition Therapeutics" with 2 trials sponsored and "Impax Laboratories, LLC" with 2 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Charter Research" #1 collaborator was "National Institute on Aging (NIA)" with 4 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Alzheimer's Association" with 1 trials as a collaborator, "Biogen" with 1 trials as a collaborator and "ClinEdge, LLC" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Charter Research" are "Alzheimer Disease" (17 trials), "Mild Cognitive Impairment" (4 trials), "Cognitive Dysfunction" (2 trials), "Early Alzheimer's Disease" (2 trials) and "Healthy" (2 trials). Many other conditions were trialed in "Charter Research" in a lesser frequency.

Most popular intervention types in "Charter Research" are "Drug" (24 trials), "Other" (7 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Donanemab" (3 trials), "CT1812" (2 trials), "NE3107" (2 trials) and "15mg T3D-959" (1 trials). Other intervention names were less common.

The vast majority of trials in "Charter Research" are 28 trials for "All" genders.

Currently, there are NaN active trials in "Charter Research". undefined are not yet recruiting, 9 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Charter Research, 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Charter Research, 4 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".